Canagliflozin and Digoxin Interaction

Drug interaction information between Canagliflozin and Digoxin.

Canagliflozin and Digoxin have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Canagliflozin and Digoxin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Canagliflozin

SGLT2 Inhibitor

Drug B

Digoxin

Cardiac Glycoside

How They Interact

Canagliflozin can increase the amount of digoxin that stays in your body.

FDA Label Information

Digoxin Clinical Impact: Canagliflozin increases digoxin exposure [see Clinical Pharmacology (12.3) ] . Intervention: Monitor patients taking INVOKANA with concomitant digoxin for a need to adjust the dosage of digoxin.

Canagliflozin Also Interacts With

View all Canagliflozin interactions →

Frequently Asked Questions

What SPL severity band is on file for Canagliflozin + Digoxin?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Digoxin has 120 labeled pairs on file vs Canagliflozin's 5. In the minor band specifically: Canagliflozin has 2 (also Lithium); Digoxin has 105 (also Metformin, Omeprazole, Ibuprofen, Diclofenac).

What mechanism field is on file for Canagliflozin and Digoxin?

Canagliflozin can increase the amount of digoxin that stays in your body.

Digoxin carries more major-labeled pairs than Canagliflozin

SPL source-record counts only. This page's band is minor · classes on file: Canagliflozin (SGLT2 Inhibitor); Digoxin (Cardiac Glycoside).

Digoxin has 2 major-labeled pairs vs Canagliflozin's 0. This page itself is in the minor band, not the major band.

Canagliflozin

0 major · 3 moderate · 2 minor · 5 total

  • Other minor peers for Canagliflozin
  • Lithium
Digoxin

2 major · 13 moderate · 105 minor · 120 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.